DZ Bank reiterated their buy rating on shares of Fresenius Medical Care (NYSE:FMS) in a research note published on Monday morning.

Other equities research analysts also recently issued reports about the company. Morgan Stanley downgraded Fresenius Medical Care from an overweight rating to an equal weight rating in a research report on Monday, December 11th. Royal Bank of Canada reiterated a hold rating and issued a $44.00 price target on shares of Fresenius Medical Care in a report on Wednesday, September 13th. Finally, Zacks Investment Research upgraded Fresenius Medical Care from a sell rating to a hold rating and set a $53.00 price target on the stock in a report on Monday, October 9th. Two investment analysts have rated the stock with a sell rating, four have assigned a hold rating and three have assigned a buy rating to the company. The company has a consensus rating of Hold and an average price target of $48.50.

Shares of Fresenius Medical Care (NYSE FMS) opened at $52.15 on Monday. Fresenius Medical Care has a 52-week low of $39.46 and a 52-week high of $52.41. The company has a debt-to-equity ratio of 0.55, a quick ratio of 0.98 and a current ratio of 1.22. The stock has a market capitalization of $31,594.93, a P/E ratio of 23.07, a price-to-earnings-growth ratio of 2.31 and a beta of 0.45.

Several hedge funds and other institutional investors have recently modified their holdings of the company. UBS Asset Management Americas Inc. raised its holdings in shares of Fresenius Medical Care by 3.6% in the second quarter. UBS Asset Management Americas Inc. now owns 2,357 shares of the company’s stock worth $114,000 after buying an additional 81 shares during the period. Sawtooth Solutions LLC raised its holdings in shares of Fresenius Medical Care by 2.9% in the second quarter. Sawtooth Solutions LLC now owns 4,887 shares of the company’s stock worth $236,000 after buying an additional 137 shares during the period. BB&T Securities LLC raised its holdings in shares of Fresenius Medical Care by 1.4% in the second quarter. BB&T Securities LLC now owns 15,053 shares of the company’s stock worth $727,000 after buying an additional 211 shares during the period. Blair William & Co. IL raised its holdings in shares of Fresenius Medical Care by 2.0% in the second quarter. Blair William & Co. IL now owns 13,638 shares of the company’s stock worth $659,000 after buying an additional 264 shares during the period. Finally, Advisor Group Inc. raised its holdings in shares of Fresenius Medical Care by 4.0% in the second quarter. Advisor Group Inc. now owns 8,168 shares of the company’s stock worth $393,000 after buying an additional 312 shares during the period. Hedge funds and other institutional investors own 3.02% of the company’s stock.

TRADEMARK VIOLATION WARNING: This article was originally reported by Watch List News and is the property of of Watch List News. If you are viewing this article on another website, it was stolen and republished in violation of U.S. & international trademark and copyright laws. The correct version of this article can be accessed at https://www.watchlistnews.com/fresenius-medical-cares-fms-buy-rating-reaffirmed-at-dz-bank/1772837.html.

Fresenius Medical Care Company Profile

Fresenius Medical Care AG & Co KGaA is a kidney dialysis company. The Company provides dialysis care and related services to persons suffering from end-stage renal disease (ESRD), as well as other healthcare services. The Company’s segments include North America Segment, the Europe, Middle East and Africa (EMEA) Segment, the Asia-Pacific Segment and the Latin America Segment.

Analyst Recommendations for Fresenius Medical Care (NYSE:FMS)

Receive News & Ratings for Fresenius Medical Care Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care and related companies with MarketBeat.com's FREE daily email newsletter.